Article in ACS nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Marian A Ackun-FarmmerRobert E. Fischell Institute for Biomedical Devices, 8278 Paint Branch Drive, College Park, Maryland 20742, United States.
Marina Willson ShirkeyDepartment of Surgery, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.
Robert S OakesRobert E. Fischell Institute for Biomedical Devices, 8278 Paint Branch Drive, College Park, Maryland 20742, United States.ORCID 0000-0003-3783-6488
Shrey Alpeshkumar ShahRobert E. Fischell Institute for Biomedical Devices, 8278 Paint Branch Drive, College Park, Maryland 20742, United States.ORCID 0000-0001-7037-6845
Camilla EdwardsRobert E. Fischell Institute for Biomedical Devices, 8278 Paint Branch Drive, College Park, Maryland 20742, United States.
Senta KapnickRobert E. Fischell Institute for Biomedical Devices, 8278 Paint Branch Drive, College Park, Maryland 20742, United States.
Sean T CareyRobert E. Fischell Institute for Biomedical Devices, 8278 Paint Branch Drive, College Park, Maryland 20742, United States.ORCID 0000-0003-1851-0300
Alexis YanesRobert E. Fischell Institute for Biomedical Devices, 8278 Paint Branch Drive, College Park, Maryland 20742, United States.
Jonathan BrombergDepartment of Surgery, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.
Christopher M JewellRobert E. Fischell Institute for Biomedical Devices, 8278 Paint Branch Drive, College Park, Maryland 20742, United States.ORCID 0000-0002-6668-6928
Funding
Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
Defining the induction and maintenance of myelin-specific tolerance in T cells and B cells using local lymph node depotsR01AI169686 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI Christopher M Jewell · 2022 to 2026
$2.8M
Improving multiple sclerosis patient quality of life using microneedle patches to simplify delivery of MS drugsR01AI144667 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI JEWELL, CHRISTOPHER M · 2019 to 2022
$1.6M
Programming immune function through modular assembly of polyionic immune signalsR01EB027143 · NIBIB · UNIV OF MARYLAND, COLLEGE PARK · PI JEWELL, CHRISTOPHER M · 2019 to 2022
$1.6M
Developing controlled release immune complexes to treat multiple sclerosisF32AI172499 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI ACKUN-FARMMER, MARIAN ADRIANA · 2023 to 2024
$105k
Combinatorial control of TLR signaling using self-assembly of immune signals on microneedle arrays to access the skin nicheF31AI176844 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI EDWARDS, CAMILLA MARIE · 2024 to 2025
$56k
Biomaterials-Enabled Delivery of Immunometabolic Modulators to Improve Treatment Options for Multiple Sclerosis in VeteransIK2BX005756 · VA · BALTIMORE VA MEDICAL CENTER · PI Senta Kapnick · 2023 to 2026
–
Leveraging nanotechnology and skin delivery to drive selective immune tolerance for Multiple SclerosisIK2BX005061 · VA · BALTIMORE VA MEDICAL CENTER · PI OAKES, ROBERT SMITH · 2020 to 2024
–
Tunable Assembly of Regulatory Immune Signals to Promote Myelin-specific ToleranceI01BX003690 · VA · BALTIMORE VA MEDICAL CENTER · PI Christopher M Jewell · 2017 to 2026
Autoimmune diseases are broadly characterized as a failure in immune tolerance. In multiple sclerosis (MS), autoreactive immune cells attack the protective myelin sheath lining neurons in the central nervous system. Therapeutic strategies that selectively and durably restore immune tolerance without broad immunosuppression are urgently needed for MS. Our lab has developed assemblies of immune constructs built entirely from myelin antigen (MOG
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Engineered Immune Constructs Alter Antigen-Specific Immune Tolerance and Confer Durable Protection in Myelin-Driven Autoimmunity. · full record | OpenQuestion